| dc.creator |
Bertrán, X. |
|
| dc.creator |
Mañé Almero, Josep |
|
| dc.creator |
Fernández Bañares, Fernando |
|
| dc.creator |
Castellà, E. |
|
| dc.creator |
Bartolí, R. |
|
| dc.creator |
Ojanguren Sabán, Isabel |
|
| dc.creator |
Esteve i Comas, Maria |
|
| dc.creator |
Gassull, Miquel Àngel |
|
| dc.date |
2011-07-07T12:30:33Z |
|
| dc.date |
2011-07-07T12:30:33Z |
|
| dc.date |
1996 |
|
| dc.date.accessioned |
2024-12-16T10:27:15Z |
|
| dc.date.available |
2024-12-16T10:27:15Z |
|
| dc.identifier |
0017-5749 |
|
| dc.identifier |
http://hdl.handle.net/2445/18658 |
|
| dc.identifier |
160920 |
|
| dc.identifier |
8984030 |
|
| dc.identifier.uri |
http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/22138 |
|
| dc.description |
BACKGROUND: 5-Lipoxygenase products play a part in inflammatory response. AIMS: The effect of intracolonic administration of zileuton (a 5-lipoxygenase inhibitor) on colonic damage and eicosanoid local release was assessed in a rat model of colitis. METHODS: Ninety rats with trinitrobenzenesulphonic acid induced colitis were randomised to receive placebo, 5-aminosalicylic acid (50 mg/kg), or zileuton (50 mg/kg) intracolonically for four weeks. Local eicosanoid release was monitored by intracolonic dialysis throughout the study. The colon was removed for macroscopic and histological assessment at weeks 1, 2, and 4 after colitis induction in 10 rats of each group. RESULTS: Zileuton significantly reduced macroscopic damage score after four weeks of treatment in comparison with the other two groups (p = 0.034). In addition, zileuton administration significantly increased the intracolonic release of both thromboxane B2 at week 1 (p = 0.05) and prostaglandin E2 at weeks 2 and 4 (p < 0.05). Zileuton and 5-aminosalicylic acid decreased leukotriene B4 release by 90% at day 3. CONCLUSIONS: Intracolonic zileuton, compared with 5-aminosalicylic acid and placebo, seems to improve the course of the disease in a model of chronic colitis. This effect may be related to an increased and maintained production of prostaglandin E2 together with inhibition of leukotriene B4 synthesis. |
|
| dc.format |
6 p. |
|
| dc.format |
application/pdf |
|
| dc.language |
eng |
|
| dc.publisher |
BMJ Group |
|
| dc.relation |
Reproducció digital del document publicat a: http://dx.doi.org/10.1136/gut.38.6.899 |
|
| dc.relation |
Gut, 1996, vol. 38, núm. 6, p. 899-904 |
|
| dc.relation |
http://dx.doi.org/10.1136/gut.38.6.899 |
|
| dc.rights |
(c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 1996 |
|
| dc.rights |
info:eu-repo/semantics/openAccess |
|
| dc.source |
Articles publicats en revistes (Medicina) |
|
| dc.subject |
Colitis |
|
| dc.subject |
Còlon |
|
| dc.subject |
Antienzims |
|
| dc.subject |
Terapèutica |
|
| dc.subject |
Colitis |
|
| dc.subject |
Colon |
|
| dc.subject |
Enzyme inhibitors |
|
| dc.subject |
Therapeutics |
|
| dc.title |
Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis |
|
| dc.type |
info:eu-repo/semantics/article |
|
| dc.type |
info:eu-repo/semantics/publishedVersion |
|